The study of sentinel lymph node detection in patients with carcinoma of uterine cervix

Abstract

16586 Background: Cervical cancer is the seventh most common cancer, overall, and the third most common in women. Lymph node status is the most important independent prognostic factor in early stage cervical cancer of uterus. Intraoperative lymphatic mapping and sentinel lymph node (SLN) detection have been increasingly evaluated in the treatment of a variety of solid tumors, particularly breast cancer and cutaneous melanoma. We investigated to evaluate the feasibility of these procedures in patients undergoing radical hysterectomy with pelvic lymphadenectomy for treatment of early cervical cancer. Methods: Patients with histologically diagnosed FIGO stage IA to IIA carcinoma of uterine cervix were enrolled to this procedure who where scheduled to go radical abdominal hysterectomy and pelvic lymphadenectomy by injecting Patent Blue Dye in cervix. Results: 30 patients were enrolled to this study. A total of 60 SLNs (mean 2.5,) were detected in 24 patients with detection rate of 80%. Bilateral SLNs were detected in 70.1% of cases. SLNs were identified in obturator and external iliac areas in 50% and 31.7%, respectively; no SLNs were discovered in the common iliac region.7 patients (23.3%) had lymph node metastases; one of these had false negative SLN.The false negative rate and negative predictive value were 14.3% and 94.4%, respectively. Conclusions: SLN detection procedure with blue dye technique is a feasible procedure in cervical cancer of uterus. Patent blue dye is cheap, safe, and effective tracer to detect sentinel node in carcinoma of cervix. No significant financial relationships to disclose.